PRINCETON, NJ / ACCESSWIRE / May 6, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be participating in the EF Hutton Annual Global Conference, which will take place on May 15, 2024 at The Plaza Hotel in New York..

新泽西州普林斯顿/ACCESSWIRE/2024年5月6日/开发创新靶向生物药物的生物制药公司Sonnet BioTherapeutics Holdings，Inc.（纳斯达克：SONN）将参加2024年5月15日在纽约广场酒店举行的EF Hutton全球年会。。

Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer, Richard Kenney, M.D., Chief Medical Officer, and Jay Cross, Chief Financial Officer, will be presenting on May 15th. Interested parties can register to attend here. Members of the Sonnet BioTherapeutics management team will also be holding one-on-one investor meetings throughout the day..

十四行诗创始人兼首席执行官Pankaj Mohan博士、首席医疗官Richard Kenney博士和首席财务官Jay Cross将于5月15日发表演讲。感兴趣的人可以在这里登记参加。十四行诗生物治疗管理团队的成员也将全天举行一对一的投资者会议。。

About Sonnet BioTherapeutics Holdings, Inc.

关于十四行诗生物治疗控股有限公司。

Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and 'hitch-hikes' on human serum albumin (HSA) for transport to target tissues.

Sonnet BioTherapeutics是一家专注于肿瘤学的生物技术公司，拥有专有平台，用于创新单功能或双功能作用的生物药物。该技术被称为FHAB（完全人白蛋白结合），它利用完全人单链抗体片段（scFv）与人血清白蛋白（HSA）结合并“搭便车”以转运至靶组织。

Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines..

Sonnet的FHAB旨在专门针对肿瘤和淋巴组织，具有改进的治疗窗口，以优化免疫调节生物药物的安全性和有效性。FHAB是模块化即插即用构建体的基础，用于增强一系列大分子治疗类别，包括细胞因子，肽，抗体和疫苗。。

About EF Hutton LLC

关于EF Hutton LLC

EF Hutton LLC is an investment bank headquartered in New York, NY, which provides strategic advisory and financing solutions to middle market and emerging growth companies. EF Hutton has a proven track record of offering superior strategic advisory to clients across the globe in any sector, with unique access to capital from the USA, Asia, Europe, UAE, and Latin America..

EF Hutton LLC是一家投资银行，总部位于纽约州纽约市，为中等市场和新兴成长型公司提供战略咨询和融资解决方案。EF Hutton拥有为全球任何行业的客户提供卓越战略咨询的良好记录，拥有从美国、亚洲、欧洲、阿联酋和拉丁美洲获得资金的独特渠道。。

EF Hutton is a leader on Wall Street, having raised over $16 billion in capital across more than 270 transactions through various product types. Since 2022, by deal count, the firm has been #1 in US IPO issuance and #1 in SPAC issuance, per Bloomberg and SPAC Insider. EF Hutton is one of the most active investment banks in the middle of the market space.

EF Hutton是华尔街的领导者，通过各种产品类型的270多笔交易筹集了超过160亿美元的资金。根据彭博社（Bloomberg）和SPAC Insider的数据，自2022年以来，根据交易数量，该公司在美国首次公开募股（IPO）发行中排名第一，在SPAC发行中排名第一。EF Hutton是市场空间中间最活跃的投资银行之一。

For more information, please visit efhutton.com..

有关更多信息，请访问efhutton.com。。

Sonnet BioTherapeutics Investor Contact:

Sonnet BioTherapeutics投资者联系人：

Jack Yauch

Jack Yauch

Solebury Strategic Communications

Solebury战略通信

862-754-1024

862-754-1024

jyauch@soleburystrat.com

jyauch@soleburystrat.com

SOURCE: Sonnet BioTherapeutics, Inc.

来源：Sonnet BioTherapeutics，Inc。

View the original press release on accesswire.com

在accesswire.com上查看原始新闻稿